November 2022 Issue | Blood Cancers Today

November 2022

November 2022

This issues of Blood Cancers Today features a Get to Know with Courtney DiNardo, MD, MSCE; meeting news from the 2022 SOHO Annual Meeting; and more.

Viewpoints

Associate Editor's Message

MRD: Hope and Reality

Features

Get to Know

Get to Know ... Courtney D. DiNardo, MD, MSCE

In Focus

Increased Knowledge Leads to Further Personalization of ALL Treatment

Point | Counterpoint

CAR-T Therapy Versus Transplant in Second-Line Relapsed/Refractory DLBCL

News

In the Literature

Baseline Genetics Are Primary Drivers of HSCT Outcomes in Older Adults with AML

Post-Transplant Maintenance with a p53 Reactivator Plus Azacitidine Leads to ‘Encouraging’ Outcomes in Patients with TP53-Mutated AML, MDS

Regulatory Actions

FDA Advisory Committee Rejects Melphalan Flufenamide for Myeloma

Biologics License Application for CTCL Treatment Submitted to the FDA

EMA Issues Positive Opinion on Loncastuximab Tesirine for DLBCL

EMA Issues Positive Opinion on Zanubrutinib for Relapsed/Refractory MZL

Meeting News

Opening SOHO Session: ‘Remarkable Number’ of Attendees at 10th Annual Meeting

Novel Therapy Gilteritinib Effective in Newly Diagnosed AML

The Future of CAR T-Cell Therapy in Lymphoma

SOHO Plenary Session: Overcoming Resistance to Targeted Therapies in CLL

Outcomes of Myelofibrosis Patients After Allogeneic HSCT in Retrospective Study

Jia Ruan, MD, PhD, Talks Emerging Treatment Options for MCL

Novel Chemotherapy Can Eliminate the Need for Transplant in ALL

The Financial Toxicity of FDA-Approved Drugs for Malignant Hematology and OPTIC Trial Results

State of the Art

Considerations for the Management of Secondary CNS Lymphoma

News Roundup

Bispecific Antibody Treatment Leads to ‘Deep and Durable’ Responses in R/R MM

Ciltacabtagene Autoleucel Demonstrates High Rates of Response, MRD Negativity in R/R MM

November 2022

Advertisement

Advertisement